Shares of Bioventus Inc. (BVS) jumped 6.71% in pre-market trading on Tuesday after the medical device company reported third-quarter earnings that exceeded analyst expectations and reaffirmed its full-year 2025 guidance.

For the third quarter, Bioventus reported revenue of $138.7 million, slightly above the consensus estimate of $138.2 million. Adjusted earnings per share came in at $0.15, significantly beating the $0.11 expected by analysts. The company's organic revenue grew 8.2% year-over-year, driven by strong performance across all three areas of its portfolio.

"Momentum continued to build across our portfolio as our team delivered an exceptional quarter reflecting above-market organic revenue growth, increased profitability, and significant cash flow acceleration," said Rob Claypoole, Bioventus President and Chief Executive Officer.

Importantly, Bioventus reaffirmed its full-year 2025 guidance, projecting net sales between $560 million and $570 million. The company also expects adjusted EBITDA of $112 million to $116 million and non-GAAP earnings per share of $0.64 to $0.68 for the year.

The strong quarterly results and optimistic outlook appear to have boosted investor confidence in Bioventus's growth trajectory. The company's focus on organic growth, improved profitability, and cash flow generation resonated well with the market, leading to the significant pre-market stock price increase.

Bioventus is a global leader in innovations for active healing, offering a diverse portfolio of products in pain treatments, surgical solutions, and restorative therapies. The company's ability to deliver growth across its segments while improving margins demonstrates the strength of its business model in the current healthcare environment.